257 related articles for article (PubMed ID: 11004090)
1. Matrix metalloproteinases and their natural inhibitors in fibrovascular membranes of proliferative diabetic retinopathy.
Salzmann J; Limb GA; Khaw PT; Gregor ZJ; Webster L; Chignell AH; Charteris DG
Br J Ophthalmol; 2000 Oct; 84(10):1091-6. PubMed ID: 11004090
[TBL] [Abstract][Full Text] [Related]
2. Differential expression and localization of human tissue inhibitors of metalloproteinases in proliferative diabetic retinopathy.
Abu El-Asrar AM; Ahmad A; Bittoun E; Siddiquei MM; Mohammad G; Mousa A; De Hertogh G; Opdenakker G
Acta Ophthalmol; 2018 Feb; 96(1):e27-e37. PubMed ID: 28391660
[TBL] [Abstract][Full Text] [Related]
3. Predominance of MMP-1 and MMP-2 in epiretinal and subretinal membranes of proliferative vitreoretinopathy.
Webster L; Chignell AH; Limb GA
Exp Eye Res; 1999 Jan; 68(1):91-8. PubMed ID: 9986746
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes.
Steen B; Sejersen S; Berglin L; Seregard S; Kvanta A
Invest Ophthalmol Vis Sci; 1998 Oct; 39(11):2194-200. PubMed ID: 9761302
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical study of extracellular matrix components in epiretinal membranes of vitreoproliferative retinopathy and proliferative diabetic retinopathy.
Ioachim E; Stefaniotou M; Gorezis S; Tsanou E; Psilas K; Agnantis NJ
Eur J Ophthalmol; 2005; 15(3):384-91. PubMed ID: 15945009
[TBL] [Abstract][Full Text] [Related]
6. Production and activation of matrix metalloproteinase-2 in proliferative diabetic retinopathy.
Noda K; Ishida S; Inoue M; Obata K; Oguchi Y; Okada Y; Ikeda E
Invest Ophthalmol Vis Sci; 2003 May; 44(5):2163-70. PubMed ID: 12714657
[TBL] [Abstract][Full Text] [Related]
7. Expression of matrix metalloproteinases and their inhibitors in experimental retinal ischemia-reperfusion injury in rats.
Zhang X; Sakamoto T; Hata Y; Kubota T; Hisatomi T; Murata T; Ishibashi T; Inomata H
Exp Eye Res; 2002 May; 74(5):577-84. PubMed ID: 12076079
[TBL] [Abstract][Full Text] [Related]
8. Expression of autotaxin and acylglycerol kinase in proliferative vitreoretinal epiretinal membranes.
Abu El-Asrar AM; Missotten L; Geboes K
Acta Ophthalmol; 2012 Mar; 90(2):e84-9. PubMed ID: 22103573
[TBL] [Abstract][Full Text] [Related]
9. [Progress in studies on effects of extracellular matrix in occurrence of proliferative vitreoretinopathy].
Wang LH; Li GL
Zhonghua Yan Ke Za Zhi; 2008 Aug; 44(8):759-63. PubMed ID: 19115640
[TBL] [Abstract][Full Text] [Related]
10. Relationship between vitreous levels of matrix metalloproteinases and vascular endothelial growth factor in proliferative diabetic retinopathy.
Abu El-Asrar AM; Mohammad G; Nawaz MI; Siddiquei MM; Van den Eynde K; Mousa A; De Hertogh G; Opdenakker G
PLoS One; 2013; 8(12):e85857. PubMed ID: 24392031
[TBL] [Abstract][Full Text] [Related]
11. Expression and distribution of MMPs and TIMPs in human uveal melanoma.
Lai K; Conway RM; Crouch R; Jager MJ; Madigan MC
Exp Eye Res; 2008 Jun; 86(6):936-41. PubMed ID: 18423620
[TBL] [Abstract][Full Text] [Related]
12. Diverse NF-kappaB expression in epiretinal membranes after human diabetic retinopathy and proliferative vitreoretinopathy.
Harada C; Harada T; Mitamura Y; Quah HM; Ohtsuka K; Kotake S; Ohno S; Wada K; Takeuchi S; Tanaka K
Mol Vis; 2004 Jan; 10():31-6. PubMed ID: 14737065
[TBL] [Abstract][Full Text] [Related]
13. Protein kinase C-mediated regulation of matrix metalloproteinase and tissue inhibitor of metalloproteinase production in a human retinal müller cells.
Miyata Y; Kase M; Sugita Y; Shimada A; Nagase T; Katsura Y; Kosano H
Curr Eye Res; 2012 Sep; 37(9):842-9. PubMed ID: 22667460
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical study of angiogenesis and proliferative activity in epiretinal membranes.
Tsanou E; Ioachim E; Stefaniotou M; Gorezis S; Charalabopoulos K; Bagli H; Peschos D; Psilas K; Agnantis NJ
Int J Clin Pract; 2005 Oct; 59(10):1157-61. PubMed ID: 16178982
[TBL] [Abstract][Full Text] [Related]
15. Extracellular matrix metalloproteinase inducer (EMMPRIN) is a potential biomarker of angiogenesis in proliferative diabetic retinopathy.
Abu El-Asrar AM; Ahmad A; Alam K; Siddiquei MM; Mohammad G; Hertogh G; Mousa A; Opdenakker G
Acta Ophthalmol; 2017 Nov; 95(7):697-704. PubMed ID: 27860331
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-6 and matrix metalloproteinase expression in the subretinal fluid during proliferative vitreoretinopathy: correlation with extent, duration of RRD and PVR grade.
Symeonidis C; Papakonstantinou E; Androudi S; Tsaousis KT; Tsinopoulos I; Brazitikos P; Karakiulakis G; Diza E; Dimitrakos SA
Cytokine; 2012 Jul; 59(1):184-90. PubMed ID: 22579111
[TBL] [Abstract][Full Text] [Related]
17. Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease.
Kirkegaard T; Hansen A; Bruun E; Brynskov J
Gut; 2004 May; 53(5):701-9. PubMed ID: 15082589
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas.
Nakano A; Tani E; Miyazaki K; Yamamoto Y; Furuyama J
J Neurosurg; 1995 Aug; 83(2):298-307. PubMed ID: 7616276
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinases and their inhibitors in the chamber angle of normal eyes and patients with primary open-angle glaucoma and exfoliation glaucoma.
Rönkkö S; Rekonen P; Kaarniranta K; Puustjärvi T; Teräsvirta M; Uusitalo H
Graefes Arch Clin Exp Ophthalmol; 2007 May; 245(5):697-704. PubMed ID: 17028863
[TBL] [Abstract][Full Text] [Related]
20. Abnormal expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in brain arteriovenous malformations.
Hashimoto T; Wen G; Lawton MT; Boudreau NJ; Bollen AW; Yang GY; Barbaro NM; Higashida RT; Dowd CF; Halbach VV; Young WL;
Stroke; 2003 Apr; 34(4):925-31. PubMed ID: 12649522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
